Predictive value of excision repair cross- complementation group 1 expression in locoregionally advanced nasopharyngeal carcinoma receiving cisplatin-based concurrent chemoradiotherapy

Article type: Research Article

Authors: Wang, Dong^{a; b; 1} | Zhou, Juan^{c; 1} | Zheng, Jihua^{c; 1} | Zhang, Jiang^b | Chen, Yaoming^b | Li, Wen^{a; *} | Wang, Ruizhi^{b; *}

Affiliations: [a] Laboratory of Department of General Surgery, The First Affiliated Hospital of Sun Yat-sen University, Guangzhou 510080, Guangdong, China | [b] Department of Laboratory Medicine, The First Affiliated Hospital of Sun Yat-sen University, Guangzhou 510080, Guangdong, China | [c] Department of Oncology, General Hospital of Guangzhou Military Command of PLA, Guangzhou 510010, Guangdong, China

Correspondence: [*] Corresponding authors: Wen Li, Laboratory of Department of General Surgery, The First Affiliated Hospital of Sun Yat-sen University, No. 58 Zhongshan 2nd Road, 510080 Guangzhou, Guangdong, China. Tel.: +86 13728048336; Fax: +86 20 87755766 8582; E-mail: [email protected],DepartmentofLaboratoryMedicine,TheFirstAffiliatedHospitalofSunYat-senUniversity,No.58Zhongshan2ndRoad,510080Guangzhou,Guangdong,China.Tel.:+8613450490973;Fax:+8620877557668582;E-mail:[email protected].

Note: [1] Equal contributors.

Abstract: BACKGROUND: Cisplatin-based concurrent chemoradiotherapy is recommended for nasopharyngeal carcinoma (NPC) at advanced stages. Excision repair cross-complementation group 1 (ERCC1) plays an important function in the repair of DNA damage that is a critical process of chemo- and radiotherapy. OBJECTIVE: This study aimed to investigate the clinical significance of ERCC1 expression in NPC treated with cisplatin-based concurrent chemoradiotherapy in locoregionally advanced NPC. METHODS: The expression level of ERCC1 and its association with clinicopathological characteristics in 205 locoregionally advanced NPC patients receiving cisplatin-based concurrent chemoradiotherapy were analyzed retrospectively. RESULTS: The correlation analysis revealed that the treatment-sensitive patients displayed dramatically lower ERCC1 expression than treatment-resistant cases did. Furthermore, the Kaplan-Meier plots revealed lower ERCC1 expression was significantly associated with better survival. Multivariate analysis further showed that the ERCC1 expression was an independent predictor of NPC patients’ survival. CONCLUSIONS: ERCC1 expression might be a useful predictive marker in patients with locoregionally advanced NPC receiving cisplatin-based concurrent chemoradiotherapy.

Keywords: ERCC1, cisplatin-based concurrent chemoradiotherapy, nasopharyngeal cancer, survival

DOI: 10.3233/CBM-170817

Journal: Cancer Biomarkers, vol. 21, no. 4, pp. 875-881, 2018